Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05851391 · ClinicalTrials.gov registry record · Phase 2
buRst-supprESsion TO Stop Refractory Status Epilepticus Post-cardiac Arrest
A Phase 2 study of Seizures and Status Epilepticus, sponsored by University of California, San Francisco.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT05851391: Recruiting Phase 2 study of Seizures and Status Epilepticus, sponsored by University of California, San Francisco.
NCT05851391 is a Phase 2 study of Seizures and Status Epilepticus that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 30 participants, below the 934-participant average among 39 other Seizures trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05851391, a Phase 2 study of Seizures and Status Epilepticus, is actively recruiting participants, sponsored by University of California, San Francisco.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
RESTORE is a randomized clinical trial investigating the safety and feasibility of using EEG treatment targets (burst suppression vs. seizure suppression) for post-cardiac arrest refractory status epilepticus treatment.
Primary Outcome
Continuous EEG will be monitored to determine time to PCARSE recurrence during the anesthetic maintenance and anesthetic weaning phase (combined)
Conditions Studied
Interventions
- DRUG Burst Suppression EEG Target Intravenous Anesthesia
- DRUG Seizure Suppression EEG Target Intravenous Anesthesia
Study Locations (1)
California
- Zuckerberg San Francisco General Hospital - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-08-07 |
| Est. Completion | 2027-04-30 |
| Phase | Phase 2 |
What NCT05851391 shows while recruiting
NCT05851391 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 934-participant average among 39 other Seizures trials with a reported enrollment target (97% lower).
The record links to 7 conditions, with Seizures appearing as the primary indexed condition, and to 2 interventions - of which Burst Suppression EEG Target Intravenous Anesthesia is the first listed.
NCT05851391 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05851391 about?
NCT05851391 is a clinical study titled "buRst-supprESsion TO Stop Refractory Status Epilepticus Post-cardiac Arrest". RESTORE is a randomized clinical trial investigating the safety and feasibility of using EEG treatment targets (burst suppression vs. seizure suppression) for post-cardiac arrest refractory status epilepticus treatment.
What is the current status of trial NCT05851391?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2023-08-07. Estimated completion is 2027-04-30.
What conditions does trial NCT05851391 study?
This clinical trial studies the following conditions: Seizures, Status Epilepticus, Heart Arrest, Hypoxia-Ischemia, Brain, Refractory Status Epilepticus.
What interventions are being tested in trial NCT05851391?
The interventions under investigation include: Burst Suppression EEG Target Intravenous Anesthesia (DRUG), Seizure Suppression EEG Target Intravenous Anesthesia (DRUG).
Who is sponsoring clinical trial NCT05851391?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05851391 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Seizures
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05851391's enrollment target sits among peer trials
30 32nd of 39 higher than 7 of 39 other Seizures trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Seizures trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PeRampanel fOr Status ePilEpticus pRophylaxis Post-cardiac Arrest
RECRUITING · Phase 2
-
Prophylactic Anti-Seizure Medication vs No Anti-Seizure Medication for Patients With Primary Motor Cortex Brain Metastases
RECRUITING · Phase 2
-
RNS System LGS Feasibility Study
ACTIVE NOT RECRUITING · Phase 2
-
Hypovitaminosis D in Neurocritical Patients
COMPLETED · Phase 2
-
Phase 2 Clinical Trial of SGS-742 Therapy in Succinic Semialdehyde Dehydrogenase Deficiency
COMPLETED · Phase 2
-
Intranasal Midazolam Versus Rectal Diazepam for Treatment of Seizures
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI